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Pseudomonas aeruginosa is an opportunistic pathogen in environmental waters with a high prevalence of multidrug resistance.
In this study the synergistic eﬃcacy of synergy antibiotic combinations in multidrug-resistant P. aeruginosa strains isolated from
an abattoir eﬄuent was investigated. Water samples were processed using membrane ﬁltration; Pseudomonas was isolated with
Pseudomonas Isolation Agar and conﬁrmed using polymerase chain reaction with specie-speciﬁc primer. Susceptibility studies
and in vitro synergy interaction testing were carried out, employing agar dilution and Etest procedure, respectively. Resistance
was noted for clinically relevant antipseudomonal agents tested. Finding from antibiotic synergy interaction studies revealed that
cefepime, imipenem, and meropenem combined with amikacin resulted in statistically signiﬁcant (P<0.0001) in vitro antibiotics
synergy interaction, indicating the possible use of this regimen in treatment of pseudomonal infections.
1.Introduction
The human opportunistic pathogen, Pseudomonas aerugi-
nosa, is a major cause of infection-related mortality among
the critically ill patients and carries the highest case fatal-
ity rate of all Gram-negative infections [1]. Pseudomonas
aeruginosa is highly ubiquitous in water systems and has
intrinsicantimicrobialresistanceduetolowoutermembrane
p e r m e a b i l i t y ,a sw e l la sa ne x t e n s i v ee ﬄux pump system
[2, 3]. P. aeruginosa demonstrates resistance to multiple
antibiotics, thereby rendering common antibiotic therapy
ineﬀective [4]. The presence of multidrug-resistant P. aerug-
inosa in an aquatic milieu may be important for immune-
suppressed or other at-risk individuals, for whom treatment
diﬃculties have greater implications [5]. Some P. aeruginosa
strains exhibit mutations in ﬂuoroquinolone binding sites,
the loss of porin channels, and increased beta-lactamase or
cephalosporinase production [2, 3]. P. aeruginosa frequently
acquires additional resistance mechanisms (plasmids) and
routinely develops multidrug resistance throughout the
course of a treatment regimen [3].
Sequentialtreatmentforinvasiveinfectionshasbeentyp-
ically considered as an option to improve results of mon-
otherapy; however, combination therapy could be an alter-
native to monotherapy for patients with invasive infections
that are diﬃcult to treat, such as those due to multiresistant
species and for those who fail to respond to standard treat-
ment. Antimicrobial compounds used in combination might
promote the eﬀectiveness of each agent, with eﬃcacy being
achieved using a lower dose of each drug. Bantar et al. [6]
studied the combination of amikacin with meropenem,
ceftazidime, cefepime, and imipenem, respectively; results
indicated that cefepime, especially in combination with ami-
kacin, displayed bactericidal properties against carbapenem-
resistant strains. The combinations with beta-lactams and
an aminoglycoside or a ﬂuoroquinolone remain a reasonable2 The Scientiﬁc World Journal
choice for treatment of invasive infections caused by P. aer-
uginosa [7].
Multidrug resistance in P. aeruginosa population is a
pervasive and growing environmental problem, which is
recognized asa threatto public health.Consequently, thereis
a need to conduct area-speciﬁc monitoring studies to proﬁle
diﬀerent pathogens responsible for speciﬁc infections and
their resistance patterns, so as to generate data that would
help clinicians to choose the correct empirical treatment. In
this study an attempt was made to investigate the antibiotics
synergy pattern of Pseudomonas aeruginosa isolated from an
abattoir in Benin-City, Nigeria.
2.MaterialandMethods
2.1. Samples Collection. The study was conducted in Benin-
City,NigeriabetweenMayandOctober,2011.Watersamples
were collected on monthly basis from the abattoir eﬄuent
prior to discharge into the receiving water body, from 100m
downstream and upstream of the discharge point. Samples
were collected in two liter (2L) plastic containers that were
previously sterilized with 70% (v/v) alcohol and rinsed with
deionised water prior to usage. During sampling, sample
containers were rinsed three times with sample water before
ﬁlling with the sample. The actual samplings were done mid-
stream by dipping each sample bottle at approximately 30
centimeter below the water surface, projecting the mouth of
the container against the ﬂow direction. After collection, the
samples were protected from direct sunlight and transported
in a cooler box containing ice packs to the laboratory for
analyses. All samples were stored at 4◦C and analyzed within
48h of sample collection.
2.2. Bacterial Isolation. Water samples were analysed for
the target bacterial pathogen using internationally accepted
techniques and principles [8]. Prior to ﬁltration, Samples
were diluted 10-fold with sterile distilled water. Fifty mil-
liliters (50mL) of the appropriate dilution of each sample
was ﬁltered through a 0.45μmp o r es i z em e m b r a n eﬁ l t e r
(Millipore), which was aseptically transferred to 45mm Petri
dishes with the appropriate selective media (Pseudomonas
Isolation Agar) and incubated at 37◦C for 48h. After incu-
bation, three to ﬁve randomly selected colonies with appro-
priate morphological characteristics were subcultured for
puriﬁcation using pseudomonas isolation agar plate which
was incubated at 37◦C for 24–48h. The pure isolates were
subjected to Gram staining and oxidase test. Only Gram-
negative bacilli and oxidase-positive isolates were selected
for biochemical reactions and using API 20 NE system.
Pseudomonas aeruginosa (ATCC 27853) was used as control.
The strips were then read, and ﬁnal identiﬁcation was made
using API lab plus software (bio Merieux, Marcy l’Etoile,
France).
2.3. Isolation of Genomic DNA. Single colonies of P. aerugi-
nosa strains grown overnight at 37◦C on Nutrient agar plates
were picked, suspended in 100μL of sterile double distilled
water and the cells were lysed using Heat Block for 15min
at 100◦C. The cell debris was removed by centrifugation at
11,000g for 2min using a MiniSpin micro centrifuge and
the supernatant used directly as template DNA or stored at
−20◦C until ready for use.
2.4. PCR Ampliﬁcation Assay. Three to ﬁve isolates were
obtained from Analytical Proﬁle Index (API 20 NE system)
identiﬁcation of P. aeruginosa isolates and conﬁrmed using
polymerase chain reaction. All PCRs were performed in
22.5μLv o l u m eo fr e a c t i o nb u ﬀer containing 0.05 unit/mL
Taq polymerase as recommended by the manufacturer
(Fermentas Life Sciences) and 2.5μL of DNA template.
Sterile double-distilled water was included in each PCR
assay as a negative control, and positive controls contained
DNA templates of P. aeruginosa ATCC 27853. All PCR was
conducted using a MultiGene Thermal Cycler (Labnet Inter-
national Inc., Edison, NJ, USA), at the following conditions:
95◦C for 1min; 40 cycles of denaturation at 95◦Cf o r1 5s ,
annealing at 58◦C for 20s; ﬁnal extension at 68◦Cf o r4 0s ,
and holding temperature of 4◦C. The primers used were:
pa722F (5 -GGCGTGGGTGTGGAAGTC-3 ) and pa899R
(5 -TGGTGGCGATCTTGAACTTCTT-3 ) amplicon size of
199bp (Lutz and Lee, 2011). Electrophoresis of amplicons
was performed with 1% agarose gel (Hispanagar, Spain)
containing ethidium bromide (EtBr) 0.5mg/L (Merck, SA)
for1hat100Vin0.5 ×TAE buﬀer(40mMTris-HCl,20mM
Na-acetate, 1mM EDTA, pH 8.5) and visualized under an
UV transilluminator (BioDoc-It System, UVP Upland, Calif
91786, USA).
2.5. Agar Dilution Susceptibility Testing. Amikacin, aztre-
onam, cefepime, ciproﬂoxacin, piperacillin-tazobactam, cef-
tazidime, imipenem, and meropenem (all clinically relevant
antimicrobial agents) were used to prepare antibiotic stock
solutionsasdescribedbyCLSI[9].A1:10dilutionwasmade
o fe a c ha n t i b i o t i cs t o c ks o l u t i o nt ob et e s t e dt oo b t a i na
ﬁnal concentration of 2,560μg/mL. An agar dilution series
(0.125-512μg/mL) was set up according to CLSI [9]p r o -
cedure. Colonies of overnight culture on Mueller-Hinton
agar medium were used to prepare and adjust inoculums as
described by CLSI [9]. Two hundred microlitres (200μL) of
each microbial suspension was placed into the wells of an
inoculum. A growth control agar plate without antibiotics
was inoculated ﬁrst; thereafter all plates were inoculated
starting with the lowest concentration. The inoculated spots
were left to dry after which the inoculated agar plates were
incubated at 37◦C for 18 to 24h.
2.6. The Minimum Inhibitory and Bactericidal Concentrations
(MICs and MBCs). The minimum inhibitory and bacteri-
cidal concentrations (MICs and MBCs) of amikacin, aztre-
onam, cefepime, ciproﬂoxacin, piperacillin-tazobactam, cef-
tazidime, imipenem, and meropenem were determined by
broth microdilution method as described by CLSI, and CLSI
criteria were used in the interpretation of the results [9].
Twofold serial dilutions, ranging from 0.125 to 256μg/mL,
for each antibiotic were prepared in Mueller Hinton broth.
The inoculum was prepared with 2-3h broth culture of each
isolate, adjusted to a turbidity equivalent to 0.5 McFarland
Standard and diluted in Mueller Hinton broth to give a ﬁnalThe Scientiﬁc World Journal 3
Table 1: Minimum inhibitory and bactericidal concentrations
(MICs and MBCs) values of Pseudomonas aeruginosa strains.
Antibiotic MIC (μg/mL)
(n = 55)
MBC (μg/mL)
(n = 55)
Amikacin 8–32 16–64
Aztreonam 8–32 16–64
Piperacillin 16–64 32–128
Piperacillin-tazobactam 16–32 32–64
Cefepime 4–8 8–32
Ceftazidime 1–8 2–16
Imipenem 2–32 4–64
Meropenem 1–8 2–16
concentration of 5 × 105 cfu/mL. MIC was deﬁned as the
lowest concentration of antibiotic to completely inhibit
visible growth. MBCs were determined by removing 10μL
samples from each well, demonstrating no visible growth,
and plated onto separate nutrient agar plates. After incuba-
tion at 37◦C for 16–20h, colonies were counted. MBC was
deﬁned as the lowest concentration of antibiotic to have at
least 99.9% killing of the initial inoculum.
2.7. Etest Synergy Assay. Thirty-ﬁve multidrug-resistant iso-
lates of P. aeruginosa were selected from agar dilution ex-
periments. For the purpose of this experiment, multidrug
resistance was deﬁned as resistance to three or more test
antibiotics.AntibioticssynergystudiesusingEteststripswere
carried out and results interpreted as described by previous
authors [10, 11]. Synergy was deﬁned as a fractional inhib-
itory concentration (FIC) index of ≤0.5; indiﬀerence was
indicated by FIC index >0.5 but ≤4, while antagonism was
deﬁned as a FIC index >4[ 10]. Antibiotics included ami-
kacin, aztreonam, piperacillin, piperacillin-tazobactam, ce-
fepime, ceftazidime, imipenem, and meropenem. Bacterial
colonies from overnight cultures were inoculated into sterile
normal saline to obtain a 0.5 McFarland (optical density)
standard. Muller Hinton agar plates were ﬂooded with this
suspension and left in a 37◦C incubator to dry for 15min.
An amikacin Etest strip was applied to the dry plate and
incubated at 35◦C for 1h. After 1h the amikacin Etest strip
was removed and a β-lactam Etest strip was placed exactly at
the same position. Plates were incubated overnight at 37◦C
a n dr e a da f t e r2 4h .
2.8. Statistical Analysis. Susceptibility data were compared
by using a Chi-square test with SPSS software for Windows,
version 17.0. Both susceptibility and resistance were calcu-
lated as percentageswith 95% conﬁdenceintervals. A P value
<0.05 was considered to be statistically signiﬁcant.
3. Results
Among the total of 75 isolated presumptive Pseudomonas
aeruginosa, by cultural and morphology characteristic, 55
were identiﬁed as Pseudomonas aeruginosa by the specie-spe-
cific primer employing PCR assay which was more sensitive
Table 2: Multidrug-resistant (MDR) pattern of P. aeruginosa.
Isolate code Multidrug-resistant proﬁle
DPT14 AMI, AZT, MEM, PIP, CEF
DPT23 AZT, PIP, IMI, CEF
DPT18 AMI, PIPT, AZT, MEM
DPT40 AMI, AZT, CEFT, PIP
DPT25 AMI, IMI, MEM, AZT
DPT15 AZT, IMI, CET, PIP
DPT8 AMI, MEM, PIPT, IMI, PIP
DPT11 CEF, IMI, MEM, PIPT
UPST30 AMI, PIPT, AZT, MEM
UPST45 CEFT, AZT, PIP, AMI, CEF
UPST5 CEFT, IMI, AZT, PIPT
DWST31 AMI, CEFT, AZT, MEM
DWST51 AMI, AZT, MEM, PIP
DWST2 AMI, MEM, IMI, PIPT
DWST30 AMI, IMI, CEF, AZT
DWST18 IMI, AZT, CEFT, AMI
DWST34 IMI, AZT, CEFT, PIP CEF
DWST6 IMI, AMI, CEFT, AZT
DWST9 MEM, IMI, AMI, PIP, AZT, CEF
DWST16 MEM, IMI, PIP, CEFT
DWST37 MEM, IMI, AZT, CEF
DWST42 PIP, CEF, IMI, AMI
DWST28 AZT, IMI, PIPT, PIP
UPST35 AMI, PIPT, PIP, CEF
UPST39 AZT, IMI, AMI, CEF, CEFT
UPST27 IMI, AMI, AZT, MEM
AbSU5 MEM, AZT, CEF, CEFT
AbSU9 IMI, AMI, PIP, AZT, CEFT
AbSU36 AMI, AZT, CEF, CEFT
AbSU48 CEF, MEM, PIP, AMI
AbSU23 CEFT, IMI, PIPT, AZT
AbWT33 AMI, IMI, MEM, AZT
AbWT8 AZT, IMI, CEF, PIP
AbWT40 AMI, MEM, AZT, CEF
AbWT45 CEF, MEM, IMI, PIP
AMI: Amikacin; AZT: Aztreonam; PIP: Piperacillin; PIPT: Piperacillin-
tazobactam; CEF: Cefepime; CEFT: Ceftazidime; IMI: Imipenem; MEM:
Meropenem.
for conﬁrmation of the isolates. Minimum inhibitory con-
centration (MIC) and minimum bactericidal concentrations
(MBCs) values of all isolates were determined (n = 55)
(Table 1). The MBC values were generally equal or one to
threetimesgreaterthanthoseofMIC.All55isolatesanalyzed
were resistant to more than three antipseudomonal agents.
Thirty-ﬁve (n = 35) multidrug-resistant (MDR) strains were
randomlyselectedforsynergytestingusingclinicallyrelevant
antibioticsincludedinthescreeningpanel;therewasMDRto
amikacin, aztreonam, piperacillin, piperacillin-tazobactam,
cefepime,ceftazidime,imipenem,andmeropenem(Table 2).4 The Scientiﬁc World Journal
Table 3: Susceptibility and synergy interaction proﬁle of multidrug-resistant P. aeruginosa.
Antimicrobial
%s e n s i t i v i t yt o
antibiotics only
(n = 35)
Antibiotic in combination with amikacin (n = 35)
% synergy % antagonism % indiﬀerence
Amikacin 5.71 ———
Aztreonam 5.71 10(0.0015) 35(0.3175) 65(0.0018)
Piperacillin 28.57 8(0.0025) 20(0.2754) 72(0.0012)
Piperacillin-tazobactam 11.42 16(0.4658) 8(0.8560) 76(0.0001)
Cefepime 11.42 82(0.0001) 1(0.3756) 17(0.0385)
Ceftazidime 20.00 8(0.0729) 67(0.0001) 25(0.5640)
Imipenem 8.57 74(<0.0001) 6(0.0867) 20(0.0265)
Meropenem 8.57 80(<0.0001) 4(0.0932) 16(0.0172)
Values in parenthesis represent (P value).
Two (5.71%) of the test isolates were sensitive to amikacin
and aztreonam. Ten (28.57%) were sensitive to piperacillin;
4(11.42%) to piperacillin-tazobactam and cefepime; 7(20%)
to ceftazidime; 3(8.57%) to imipenem and meropenem as
shown in Table 3. Statistically signiﬁcant indiﬀerence inter-
action was observed with aztreonam, piperacillin, and pip-
eracillin-tazobactam in combination with amikacin P values
0.0018, 0.0012, and 0.0001, respectively. Cefepime, imipe-
nem, and meropenem in combination with amikacin re-
sulted in statistically signiﬁcant in vitro antibiotics synergy
interaction; P values 0.0001, <0.0001, and <0.0001, respec-
tively. A combination of ceftazidime with amikacin resulted
in signiﬁcant antagonistic interaction P<0.0001 (Table 3).
4. Discussion
P. aeruginosa is inherently resistant to many antimicrobial
agents, mainly due to the synergy between multidrug eﬄux
system or a type1 AmpC β-lactamase and low outer mem-
brane permeability [12, 13]. The results of this study indicate
that environmental P. aeruginosa isolated from an abattoir
eﬄuent has considerable levels of antibiotic resistance. Iso-
latesdemonstratedresistancetoawiderangeofclinicallyrel-
evant antimicrobial agents, including amikacin, aztreonam,
piperacillin, piperacillin-tazobactam, cefepime, ceftazidime,
imipenem, and meropenem. Although P. aeruginosa is a
model of antimicrobial resistance (due to a number of in-
trinsic factors), past research has found that the degree of
resistance to antipseudomonal agents varies considerably.
The current results are similar to past studies, which have
found analogous prevalence levels of resistant P. aeruginosa
in both the hospital and larger community [3, 14]. Although
the levels of resistance among our test isolates were similar
to those previously reported, it is important to draw the
distinctionbetweenanosocomialsettingandthenonclinical,
nonoutbreak, abattoir setting of the present study. In clinical
situation, there is constant selective pressure to enhance
the proliferation of multidrug-resistant strains. Known that
P. aeruginosa has both intrinsic resistance and a dynamic
ability to develop resistance during the course of infection,
a high frequency of resistance is now expected in hospitals.
However,inthenonclinicalenvironmentssuchaswastewater
eﬄuents and eﬄuents from pharmaceutical industries, the
presence of selective pressure has also increased antimicro-
bial resistance levels [15]. The presence of resistance of these
environmental isolates to front-line antipseudomonal drugs
may pose threat to the environment and to the receiving
water body as these waste eﬄuents are freely discharged into
the environment.
In comparison with other previous studies [10, 11, 16],
cefepime, imipenem, and meropenem in combination with
amikacin exhibited remarkable synergy interaction (P =
0.0001 and P<0.0001, resp.), and this could possibly be due
to eﬄux activity particularly that of the multisubstrate eﬄux
MexE-MexT-OprN [17], indicating the possible use of this
procedure in treatment of pseudomonal infections. In light
of the emerging resistance to carbapenems (imipenem and
meropenem) and the limited utility of overcoming this resis-
tance through prolonged infusion of high-dose carbapenem
monotherapy, combination therapy may play a role in the
treatment of infections associated with P. aeruginosa since
it may provide the potential for synergistic eﬀects between
two diﬀerent classes of anti-infectives [18]. Ceftazidime in
combination with amikacin exhibited signiﬁcant antagonis-
ticinteraction(P = 0.0001),makingthiscombinationanun-
likely choice to treat invasive pseudomonal infections. How-
ever the antagonistic interaction with ceftazidime could be
indicative of the presence of mutational derepression of Amp
C type chromosomal β-lactamase or established integron-
borne class A β-lactamase such as GES-2 [19, 20]. The pres-
ence of multidrug P. aeruginosa observed shows that this
organism is a reality to deal with cautiously in the abattoir
setting. Combination antimicrobial therapy with bacterici-
dal activity is a common strategy often employed in an
attempt to ensure reliable synergy or additive eﬀects for the
treatment of MDR P. aeruginosa infections and may reduce
emergence of resistant strains during treatment. Antibiotic
combinations including a β-lactam (cefepime), carbapen-
ems (imipenem and meropenem), and an aminoglycoside
(amikacin) havefrequentlyproducedanincreasedsynergism
eﬀect in vitro in experimental models of aerobic Gram-
negative bacillary infections. It has been suggested thatThe Scientiﬁc World Journal 5
such combinations are necessary in order to prevent the
emergenceofresistanceduringtherapy.Thesynergisticeﬀect
could be as a result of weakening of cell wall or membrane
components [21]. The ﬁndings of this study demonstrate the
potential value and necessity of closely monitoring multi-
drug-resistant pathogens in an eﬄuent environment given
their public health signiﬁcance.
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